Furthermore, Kamari et al. [36] reported that lack of IL1α or IL1β inhibits the progression of NASH in mice, while Mridha et al. [37] showed that the inhibitor of NLR family pyrin domain containing 3 (Nlrp3), which processes IL1β, reduces liver inflammation and fibrosis in experimental NASH in mice. Here, NLRP3 is linked to metabolic dysfunction-associated steatohepatitis.